CTXR - キティウス・ファ―マシュ―ティカルズ (Citius Pharmaceuticals Inc.) キティウス・ファ―マシュ―ティカルズ

 CTXRのチャート


 CTXRの企業情報

symbol CTXR
会社名 Citius Pharmaceuticals Inc (キティウス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Citius Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products adjunctive cancer care and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30 2016 the Company had not generate any revenues.   キティウス・ファ―マシュ―ティカルズは米国の特殊医薬品メ―カ―。抗感染症薬、がん補助療法、処方薬に焦点を置いた治療薬の開発や商品化に従事する。開発中の薬剤には、カテ―テル関連血流感染を対象とした抗菌薬ロックソリュ―ション「Mino-Lok」や、痔核治療での炎症や麻酔痛を軽減するヒドロコルチゾン-リドカイン局所製剤がある。本社所在地はニュ―ジャ―ジ―州。   
本社所在地 11 Commerce Drive First Floor Cranford NJ 07016 USA
代表者氏名 Leonard L. Mazur Leonard L. Mazur
代表者役職名 Executive Chairman of the Board Secretary
電話番号 +1 908-967-6677
設立年月日 40422
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 7人
url www.citiuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/ctxr
adr_tso
EBITDA EBITDA(百万ドル) -12.52810
終値(lastsale) 1.7899
時価総額(marketcap) 28994216.0109
時価総額 時価総額(百万ドル) 27.69993
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 25.11109
当期純利益 当期純利益(百万ドル) -12.73298
決算概要 決算概要 BRIEF: For the nine months ended 30 June 2018 Citius Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $9.7M. Higher net loss reflects Research and Development increase of 96% to $4.8M (expense) General and administrative increase of 8% to $4.7M (expense) Gain/Loss on Derivatives - Hedging decrease from $309K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$1.48 to -$1.01.

 CTXRのテクニカル分析


 CTXRのニュース

   Citius Pharmaceuticals : CTXR Fact Sheet | MarketScreener  2020/07/15 16:41:04 MarketScreener
NASDAQ: CTXR Investor Relations Contact: Andrew Scott, VP Corporate… | July 15, 2020
   Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Citius Pharmaceuticals : CTXR Presentation - Summer 2020 | MarketScreener  2020/05/19 13:33:04 MarketScreener
Citius Pharmaceuticals, Inc. Corporate Presentation Summer 2020 … | May 19, 2020
   Citius Pharmaceuticals : CTXR Presentation - Spring 2020 | MarketScreener  2020/04/21 18:18:06 MarketScreener
or port - related bacteremia or fungemia Complicated … | April 21, 2020
   Citius Pharmaceuticals : Quarterly report pursuant to Section 13 or 15(d) | MarketScreener  2020/02/13 22:00:43 MarketScreener
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR… | February 13, 2020
   Citius Pharmaceuticals : CTXR Fact Sheet | MarketScreener  2020/07/15 16:41:04 MarketScreener
NASDAQ: CTXR Investor Relations Contact: Andrew Scott, VP Corporate… | July 15, 2020
   Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Citius Pharmaceuticals : CTXR Presentation - Summer 2020 | MarketScreener  2020/05/19 13:33:04 MarketScreener
Citius Pharmaceuticals, Inc. Corporate Presentation Summer 2020 … | May 19, 2020
   Citius Pharmaceuticals : CTXR Presentation - Spring 2020 | MarketScreener  2020/04/21 18:18:06 MarketScreener
or port - related bacteremia or fungemia Complicated … | April 21, 2020
   Citius Pharmaceuticals : Quarterly report pursuant to Section 13 or 15(d) | MarketScreener  2020/02/13 22:00:43 MarketScreener
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR… | February 13, 2020
   Citius Pharmaceuticals : CTXR Fact Sheet | MarketScreener  2020/07/15 16:41:04 MarketScreener
NASDAQ: CTXR Investor Relations Contact: Andrew Scott, VP Corporate… | July 15, 2020
   Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Citius Pharmaceuticals : CTXR Presentation - Summer 2020 | MarketScreener  2020/05/19 13:33:04 MarketScreener
Citius Pharmaceuticals, Inc. Corporate Presentation Summer 2020 … | May 19, 2020
   Citius Pharmaceuticals : CTXR Presentation - Spring 2020 | MarketScreener  2020/04/21 18:18:06 MarketScreener
or port - related bacteremia or fungemia Complicated … | April 21, 2020
   Citius Pharmaceuticals : Quarterly report pursuant to Section 13 or 15(d) | MarketScreener  2020/02/13 22:00:43 MarketScreener
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR… | February 13, 2020

 関連キーワード  (医薬品 米国株 キティウス・ファ―マシュ―ティカルズ CTXR Citius Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)